Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;22(5):198-213.
doi: 10.1007/s12471-014-0549-5.

New antiarrhythmic targets to control intracellular calcium handling

Affiliations

New antiarrhythmic targets to control intracellular calcium handling

H E Driessen et al. Neth Heart J. 2014 May.

Abstract

Sudden cardiac death due to ventricular arrhythmias is a major problem. Drug therapies to prevent SCD do not provide satisfying results, leading to the demand for new antiarrhythmic strategies. New targets include Ca(2+)/Calmodulin-dependent protein kinase II (CaMKII), the Na/Ca exchanger (NCX), the Ryanodine receptor (RyR, and its associated protein FKBP12.6 (Calstabin)) and the late component of the sodium current (I Na-Late ), all related to intracellular calcium (Ca(2+)) handling. In this review, drugs interfering with these targets (SEA-0400, K201, KN-93, W7, ranolazine, sophocarpine, and GS-967) are evaluated and their future as clinical compounds is considered. These new targets prove to be interesting; however more insight into long-term drug effects is necessary before clinical applicability becomes reality.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Action potential and ion currents. Phases of the action potential and the responsible ion currents are discussed in the text
Fig. 2
Fig. 2
Calcium handling. 0; Sodium enters the cell, creating the AP upstroke. 1; Calcium enters via the LTCC facilitating the plateau phase of the AP and initiating CICR. 2; via RyR on the sarcoplasmic reticulum leading to 3; calcium binding to the contractile elements: excitation-contraction coupling. 4; NCX transports calcium from the cell in exchange for sodium. 5; calcium is pumped back into the SR via SERCA, together with 4 this leads to relaxation of the contractile elements and the end of the plateau phase. 6; Potassium restores the negative membrane potential
Fig. 3
Fig. 3
a EAD and DAD formation. SR calcium overload leads to increased [Ca2+]i. This can lead to prolonged action potential duration creating a calcium window current potentially leading to EAD (3). Increased [Ca2+]i on the other hand can lead to spontaneous calcium release via CICR resulting in either EADs (4) or DADs (2) via NCX. Also, late I na is able to increase [Ca]i via NCXr, hereby contributing to EAD formation. Numbers corresponding to black numbers in b. b 1; normal action potential and I CaL and I NCX. 2; DAD occurring due to forward NCX activity (*). 3; EAD due to calcium window current via LTCC (**). 4; EAD due to forward NCX activity (***)
Fig. 4
Fig. 4
a RyR open probability, [Ca2+]SR, and sparks. Calcium sparks occur when [Ca2+]SR reaches RyR opening threshold. RyR opening threshold is influenced by the open probability of RyR. Higher open probability lowers the threshold. [Ca2+]SR is affected by total [Ca2+]in and SERCA. b In heart failure [Ca2+]SR is lowered but the RyR open threshold is lowered more extensively rendering [Ca2+]SR higher then threshold
Fig. 5
Fig. 5
Schematic overview of experimental approaches that have been performed to test efficacy and antiarrhythmic potency of drugs targeting NCX, RyR, CamKII and late INa. References are stated behind the model. S stands for suppressive, P stands for preventive. Asterisk indicates papers in which no plasma concentration was measured. Dagger indicates model in which proarrhythmic events were observed

Similar articles

Cited by

References

    1. Currie S, Elliott EB, Smith GL, et al. Two candidates at the heart of dysfunction: the ryanodine receptor and calcium/calmodulin protein kinase ii as potential targets for therapeutic intervention-an in vivo perspective. Pharmacol Ther. 2011;131:204–220. doi: 10.1016/j.pharmthera.2011.02.006. - DOI - PubMed
    1. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482. doi: 10.1056/NEJMra000650. - DOI - PubMed
    1. Sen-Chowdhry S, McKenna WJ. Sudden death from genetic and acquired cardiomyopathies. Circulation. 2012;125:1563–1576. doi: 10.1161/CIRCULATIONAHA.111.025528. - DOI - PubMed
    1. Kamath GS, Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog Cardiovasc Dis. 2008;50:439–448. doi: 10.1016/j.pcad.2007.12.001. - DOI - PubMed
    1. Antoons G, Oros A, Bito V, et al. Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment. J Electrocardiol. 2007;40:S8–S14. doi: 10.1016/j.jelectrocard.2007.05.022. - DOI - PubMed

LinkOut - more resources